Cytokeratin 19 Fragment Predicts the Efficacy of Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor in Non–Small-Cell Lung Cancer Harboring EGFR Mutation-Reference-Cited by-同舟云学术

Cytokeratin 19 Fragment Predicts the Efficacy of Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor in Non–Small-Cell Lung Cancer Harboring EGFR Mutation

Published:2013-07 Issue:7 Volume:8 Page:892-898
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Tanaka Kosuke,Hata Akito,Kaji Reiko,Fujita Shiro,Otoshi Takehiro,Fujimoto Daichi,Kawamura Takahisa,Tamai Koji,Takeshita Jumpei,Matsumoto Takeshi,Monden Kazuya,Nagata Kazuma,Otsuka Kyoko,Nakagawa Atsushi,Tachikawa Ryo,Otsuka Kojiro,Tomii Keisuke,Katakami Nobuyuki

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference39 articles.

1. Cancer burden in the year 2000: the global picture;Parkin;Eur J Cancer,2001

2. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

3. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

4. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

5. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence;Mitsudomi;J Clin Oncol,2005

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comprehensive Review of Protein Biomarkers for Invasive Lung Cancer;Current Oncology;2024-08-23

2. Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations;Neoplasia;2024-07

3. Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008–2022 update;Tumor Biology;2023-10-28

4. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitor in the treatment of patients with nonsmall cell lung cancer;Medicine;2023-09-22

5. Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study;Targeted Oncology;2023-08-23